[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing",
    "summary": "The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=fe54652e01f7144501b883b0d704b46ae91ae1c10072f93eae48d1c63fbb21cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750715103,
      "headline": "Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing",
      "id": 135492035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=fe54652e01f7144501b883b0d704b46ae91ae1c10072f93eae48d1c63fbb21cd"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Shares Fall on Weight-Loss Drug Tummy Troubles",
    "summary": "At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.",
    "url": "https://finnhub.io/api/news?id=9a1532c9b7acdd1fddda703e9cdca95baa0515f6dc3cd918b96c24a031a5f8c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750709700,
      "headline": "Amgen Shares Fall on Weight-Loss Drug Tummy Troubles",
      "id": 135486657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.",
      "url": "https://finnhub.io/api/news?id=9a1532c9b7acdd1fddda703e9cdca95baa0515f6dc3cd918b96c24a031a5f8c1"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
    "summary": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
    "url": "https://finnhub.io/api/news?id=f25d8a2b9e288fb49d127c8391a9611c43c3daf14d4ba9b131e6a25874402f6d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750706210,
      "headline": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "id": 135498556,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "url": "https://finnhub.io/api/news?id=f25d8a2b9e288fb49d127c8391a9611c43c3daf14d4ba9b131e6a25874402f6d"
    }
  },
  {
    "ts": null,
    "headline": "HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?",
    "summary": "Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?",
    "url": "https://finnhub.io/api/news?id=a725160509dd8d691c83b6e1599c8673e410d03163cd721b6c7b73a66c2bd462",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750704600,
      "headline": "HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?",
      "id": 135486660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?",
      "url": "https://finnhub.io/api/news?id=a725160509dd8d691c83b6e1599c8673e410d03163cd721b6c7b73a66c2bd462"
    }
  },
  {
    "ts": null,
    "headline": "Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment",
    "summary": "Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=731535931fe6e0fad4df2a157e1e3b4e0556bad018d45fa3cb2bdac0b20606ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750703415,
      "headline": "Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment",
      "id": 135487200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=731535931fe6e0fad4df2a157e1e3b4e0556bad018d45fa3cb2bdac0b20606ee"
    }
  },
  {
    "ts": null,
    "headline": "LifeMD: Getting Frothy",
    "summary": "Discover if LifeMD, Inc.'s impressive 2025 rally is worth chasing or if profit-taking is due. Click for my updated look at LFMD stock prospects.",
    "url": "https://finnhub.io/api/news?id=09118280a4ec2f38a4b415fd1f28acc3d359b8ce30ad624496fde198e16ad2ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750701230,
      "headline": "LifeMD: Getting Frothy",
      "id": 135485403,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325246931/image_1325246931.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover if LifeMD, Inc.'s impressive 2025 rally is worth chasing or if profit-taking is due. Click for my updated look at LFMD stock prospects.",
      "url": "https://finnhub.io/api/news?id=09118280a4ec2f38a4b415fd1f28acc3d359b8ce30ad624496fde198e16ad2ab"
    }
  },
  {
    "ts": null,
    "headline": "Novo–Hims & Hers deal ends, Eli Lilly GLP-1 pill: What to know",
    "summary": "Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of off-brand compounded weight-loss drugs. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Catalysts to explain why Novo pulled out and what it means for the future of Hims & Hers and telehealth in the GLP-1 space. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here.",
    "url": "https://finnhub.io/api/news?id=822a8b30a60fa896e84a53d213be473af487da6d2b826e214ae85ea697010804",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750696672,
      "headline": "Novo–Hims & Hers deal ends, Eli Lilly GLP-1 pill: What to know",
      "id": 135483905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of off-brand compounded weight-loss drugs. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Catalysts to explain why Novo pulled out and what it means for the future of Hims & Hers and telehealth in the GLP-1 space. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here.",
      "url": "https://finnhub.io/api/news?id=822a8b30a60fa896e84a53d213be473af487da6d2b826e214ae85ea697010804"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly seeks green light for weekly insulin after strong trial results",
    "summary": "While still an injectable, once-weekly dosing offers a simpler treatment regimen for patients.",
    "url": "https://finnhub.io/api/news?id=5f8a0dc1ac88b5ee8428a5bbc1363b1e0f194a546533c0442fb098c2a4bd9496",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750694497,
      "headline": "Eli Lilly seeks green light for weekly insulin after strong trial results",
      "id": 135486676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While still an injectable, once-weekly dosing offers a simpler treatment regimen for patients.",
      "url": "https://finnhub.io/api/news?id=5f8a0dc1ac88b5ee8428a5bbc1363b1e0f194a546533c0442fb098c2a4bd9496"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal",
    "summary": "Novo Nordisk ends deal with Hims & Hers over compounded GLP-1 sales.",
    "url": "https://finnhub.io/api/news?id=899d635e760ac1130cb53b2a6b74469d1032a5363b8a8fed070eb953ccef4f26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750693190,
      "headline": "Hims & Hers stock plunges after Novo Nordisk ends Wegovy direct sales deal",
      "id": 135486681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk ends deal with Hims & Hers over compounded GLP-1 sales.",
      "url": "https://finnhub.io/api/news?id=899d635e760ac1130cb53b2a6b74469d1032a5363b8a8fed070eb953ccef4f26"
    }
  },
  {
    "ts": null,
    "headline": "Lilly declares third-quarter 2025 dividend",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock.",
    "url": "https://finnhub.io/api/news?id=d1b6e23dd9c3016cbddc197f8cbe2c1de4aa46bc042e75e3f9dce32da71a535f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750693020,
      "headline": "Lilly declares third-quarter 2025 dividend",
      "id": 135492041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock.",
      "url": "https://finnhub.io/api/news?id=d1b6e23dd9c3016cbddc197f8cbe2c1de4aa46bc042e75e3f9dce32da71a535f"
    }
  },
  {
    "ts": null,
    "headline": "‘Quality’ Stocks Just Ain’t What They Used to Be",
    "summary": "FEATURE  “Quality” stocks are supposed to perform well in a volatile market. That hasn’t been the case this year.   This year’s market has certainly been volatile. Between President Donald Trump’s tariffs, the debate over the “One Big Beautiful Bill,” and the war between Israel and Iran, it has been a choppy ride for the which has managed a small gain this year despite a 19% drop earlier this year.",
    "url": "https://finnhub.io/api/news?id=75a840657f9865c412818c7506b10eee02569d3b6b3ed3cf201bc75ec6d11c4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750691340,
      "headline": "‘Quality’ Stocks Just Ain’t What They Used to Be",
      "id": 135487614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FEATURE  “Quality” stocks are supposed to perform well in a volatile market. That hasn’t been the case this year.   This year’s market has certainly been volatile. Between President Donald Trump’s tariffs, the debate over the “One Big Beautiful Bill,” and the war between Israel and Iran, it has been a choppy ride for the which has managed a small gain this year despite a 19% drop earlier this year.",
      "url": "https://finnhub.io/api/news?id=75a840657f9865c412818c7506b10eee02569d3b6b3ed3cf201bc75ec6d11c4a"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Drops on Weight-Loss Data. Why Investors Have Doubts.",
    "summary": "Appearing at the American Diabetes Association’s annual Scientific Sessions on Sunday, Novo presented trial results for its experimental treatment CagriSema.  Patients with chronic obesity who adhered to treatment saw a mean weight loss of 22.7% at 68 weeks, compared with 2.3% in a placebo group, Novo said.  Regardless of adherence, those treated with CagriSema achieved “statistically significant weight loss” of 20.4% in the same period versus 3% for the placebo group.",
    "url": "https://finnhub.io/api/news?id=77a99a87bf05ff3c53bf0ea0a8656e485778ec6db5289343f80a2d2a7423e80b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750688760,
      "headline": "Novo Nordisk Stock Drops on Weight-Loss Data. Why Investors Have Doubts.",
      "id": 135481665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Appearing at the American Diabetes Association’s annual Scientific Sessions on Sunday, Novo presented trial results for its experimental treatment CagriSema.  Patients with chronic obesity who adhered to treatment saw a mean weight loss of 22.7% at 68 weeks, compared with 2.3% in a placebo group, Novo said.  Regardless of adherence, those treated with CagriSema achieved “statistically significant weight loss” of 20.4% in the same period versus 3% for the placebo group.",
      "url": "https://finnhub.io/api/news?id=77a99a87bf05ff3c53bf0ea0a8656e485778ec6db5289343f80a2d2a7423e80b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility",
    "summary": "Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility",
    "url": "https://finnhub.io/api/news?id=e7997b99c55b5c14893459a635e06c00b318c1e0514f7585a450cdaef2fb5a1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750683333,
      "headline": "Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility",
      "id": 135484201,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e7997b99c55b5c14893459a635e06c00b318c1e0514f7585a450cdaef2fb5a1d"
    }
  },
  {
    "ts": null,
    "headline": "Novo abruptly ends obesity drug deal with Hims",
    "summary": "The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.",
    "url": "https://finnhub.io/api/news?id=6619996c20e2bbae590ae6f861a5385857e4cb3656e7f55ad75d5d1068d3edb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750679014,
      "headline": "Novo abruptly ends obesity drug deal with Hims",
      "id": 135483923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo resolved its shortage.",
      "url": "https://finnhub.io/api/news?id=6619996c20e2bbae590ae6f861a5385857e4cb3656e7f55ad75d5d1068d3edb4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares fall as obesity pipeline faces investor scrutiny",
    "summary": "LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly's pipeline.  Novo on Sunday said full results from two late-stage trials of CagriSema - one in people with obesity or overweight, the other in overweight type 2 diabetics - showed mainly mild-to-moderate side effects and positive outcomes on blood sugar.  Jefferies called the updates \"incremental\" and flagged concerns over tolerability, as CagriSema caused slightly more nausea than both Novo's blockbuster obesity injection Wegovy and Lilly's rival therapy Zepbound.",
    "url": "https://finnhub.io/api/news?id=0ec987bb083b76411e7ffbe476f97e5441c06fbded2cc61b952d2207b9b85c2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750674061,
      "headline": "Novo Nordisk shares fall as obesity pipeline faces investor scrutiny",
      "id": 135481666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly's pipeline.  Novo on Sunday said full results from two late-stage trials of CagriSema - one in people with obesity or overweight, the other in overweight type 2 diabetics - showed mainly mild-to-moderate side effects and positive outcomes on blood sugar.  Jefferies called the updates \"incremental\" and flagged concerns over tolerability, as CagriSema caused slightly more nausea than both Novo's blockbuster obesity injection Wegovy and Lilly's rival therapy Zepbound.",
      "url": "https://finnhub.io/api/news?id=0ec987bb083b76411e7ffbe476f97e5441c06fbded2cc61b952d2207b9b85c2b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Oral GLP-1 Orforglipron Meets Key Goals in Phase 3 Diabetes Study",
    "summary": "Eli Lilly (LLY) said Saturday its oral GLP-1, orforglipron, met the primary endpoint in a phase 3 tr",
    "url": "https://finnhub.io/api/news?id=e81190f9c75ca3dcbfc5a9e887d030b0b53e6b0df4a0f5794e73183455f84f64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750672381,
      "headline": "Lilly's Oral GLP-1 Orforglipron Meets Key Goals in Phase 3 Diabetes Study",
      "id": 135481667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Saturday its oral GLP-1, orforglipron, met the primary endpoint in a phase 3 tr",
      "url": "https://finnhub.io/api/news?id=e81190f9c75ca3dcbfc5a9e887d030b0b53e6b0df4a0f5794e73183455f84f64"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: IAG, Novo Nordisk, Shell, Stellantis, LVMH",
    "summary": "Chaos in the Middle East was guiding markets on Monday, with airlines and oil on high alert.",
    "url": "https://finnhub.io/api/news?id=fe970debf1499bbeb602a01243433f36534ffef6e986cbce90dc1ffd6de78823",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750670320,
      "headline": "Trending tickers: IAG, Novo Nordisk, Shell, Stellantis, LVMH",
      "id": 135481668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Chaos in the Middle East was guiding markets on Monday, with airlines and oil on high alert.",
      "url": "https://finnhub.io/api/news?id=fe970debf1499bbeb602a01243433f36534ffef6e986cbce90dc1ffd6de78823"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Jefferies still a buyer",
    "summary": "Jefferies has confirmed its buy rating on Eli Lilly shares with an unchanged target price of $1,057.The analyst reports that the full presentation of phase 3 data for orforglipron in type 2 diabetes...",
    "url": "https://finnhub.io/api/news?id=634b32d6e0daff62d7e0213109cd0eda0679a39e03484f4d2518e45e7a2813bf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750669405,
      "headline": "Eli Lilly: Jefferies still a buyer",
      "id": 135475019,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Jefferies has confirmed its buy rating on Eli Lilly shares with an unchanged target price of $1,057.The analyst reports that the full presentation of phase 3 data for orforglipron in type 2 diabetes...",
      "url": "https://finnhub.io/api/news?id=634b32d6e0daff62d7e0213109cd0eda0679a39e03484f4d2518e45e7a2813bf"
    }
  },
  {
    "ts": null,
    "headline": "Macquarie Large Cap Growth Fund Q1 2025 Commentary",
    "summary": "Macquarie Large Cap Growth Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=3672e9429c3b47589cc93af1291ae2cd7a11c86d73d3bdb371ab65cf82b91f9a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750666560,
      "headline": "Macquarie Large Cap Growth Fund Q1 2025 Commentary",
      "id": 135474708,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3672e9429c3b47589cc93af1291ae2cd7a11c86d73d3bdb371ab65cf82b91f9a"
    }
  },
  {
    "ts": null,
    "headline": "Megablockbusters are the holy grail. Here’s how drugmakers are getting there.",
    "summary": "More drugs surpassed $10 billion in revenue last year than ever before.",
    "url": "https://finnhub.io/api/news?id=d87b3d9397c12f681650b3fd5e8ac638a952cf8219cdfd2cc8d64ab65cb360b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750665600,
      "headline": "Megablockbusters are the holy grail. Here’s how drugmakers are getting there.",
      "id": 135481669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "More drugs surpassed $10 billion in revenue last year than ever before.",
      "url": "https://finnhub.io/api/news?id=d87b3d9397c12f681650b3fd5e8ac638a952cf8219cdfd2cc8d64ab65cb360b5"
    }
  },
  {
    "ts": null,
    "headline": "Fulgent Genetics: A 'Sum Of The Parts' Story",
    "summary": "Fulgent Genetics: A 'Sum Of The Parts' Story",
    "url": "https://finnhub.io/api/news?id=aac42affe6751cd94368f1fce7cce93bf6ecd7053787543a0477e7ab948efe00",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750661178,
      "headline": "Fulgent Genetics: A 'Sum Of The Parts' Story",
      "id": 135474106,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=aac42affe6751cd94368f1fce7cce93bf6ecd7053787543a0477e7ab948efe00"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: positive results for oral orforglipron",
    "summary": "Eli Lilly reports that a Phase 3 trial has demonstrated the efficacy of orforglipron in adults with type 2 diabetes that is poorly controlled by diet and exercise alone.All three doses tested ...",
    "url": "https://finnhub.io/api/news?id=f36d72d068697fe6734d049e20f9ebbd9454cf03967cf7e08b52b8907b63e240",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750659329,
      "headline": "Eli Lilly: positive results for oral orforglipron",
      "id": 135473896,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly reports that a Phase 3 trial has demonstrated the efficacy of orforglipron in adults with type 2 diabetes that is poorly controlled by diet and exercise alone.All three doses tested ...",
      "url": "https://finnhub.io/api/news?id=f36d72d068697fe6734d049e20f9ebbd9454cf03967cf7e08b52b8907b63e240"
    }
  },
  {
    "ts": null,
    "headline": "Lilly To Acquire Verve For One-Time Cardiovascular Treatments",
    "summary": "Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up […]",
    "url": "https://finnhub.io/api/news?id=fda4a44cf25796004dbe42bf48086fe7ab173c134a4c2b439e2718289887c396",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750657207,
      "headline": "Lilly To Acquire Verve For One-Time Cardiovascular Treatments",
      "id": 135473107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up […]",
      "url": "https://finnhub.io/api/news?id=fda4a44cf25796004dbe42bf48086fe7ab173c134a4c2b439e2718289887c396"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: positive results for efsitora alfa insulin",
    "summary": "Eli Lilly has announced that Phase 3 clinical trials have demonstrated the efficacy and safety of its investigational weekly insulin efsitora alfa in adults with type-2 diabetes. In each study,...",
    "url": "https://finnhub.io/api/news?id=75a3db5f67845d7b0b00e9aede0ad6244dbda0b7153bce71bb6188055d8b0b33",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750657057,
      "headline": "Eli Lilly: positive results for efsitora alfa insulin",
      "id": 135473705,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that Phase 3 clinical trials have demonstrated the efficacy and safety of its investigational weekly insulin efsitora alfa in adults with type-2 diabetes. In each study,...",
      "url": "https://finnhub.io/api/news?id=75a3db5f67845d7b0b00e9aede0ad6244dbda0b7153bce71bb6188055d8b0b33"
    }
  },
  {
    "ts": null,
    "headline": "Lilly ADA Investor Presentation",
    "summary": "Lilly ADA Investor Presentation",
    "url": "https://finnhub.io/api/news?id=4e87cf858c2ca8cf25041f893431131a85e1e4708f587c367978256849ab1eee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750652838,
      "headline": "Lilly ADA Investor Presentation",
      "id": 135473482,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4e87cf858c2ca8cf25041f893431131a85e1e4708f587c367978256849ab1eee"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript",
    "summary": "Eli Lilly and Company (NYSE:LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22,...",
    "url": "https://finnhub.io/api/news?id=571f333b63d15e9a558499559d4009889efd5be1e83462df852fc2600c85182d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750652702,
      "headline": "Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript",
      "id": 135472797,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22,...",
      "url": "https://finnhub.io/api/news?id=571f333b63d15e9a558499559d4009889efd5be1e83462df852fc2600c85182d"
    }
  }
]